How efective are drugs?
Gene PreDiT is dedicated to the development of a new targeted treatment for obesity. We believe in improving human health by identifying novel biomarkers and new therapeutic strategies that allow for the development of safe, personalized, therefore more effective, therapies, thus contributing to a better prognosis.
-
10% Patients have large benefit
-
30% Patients have mixed benefit and harm
-
50% non-responders
-
10% patients suffer from side effects (no benefit)
OUR TEAM
André Faustino
Joana Branco
Rita Videira
News & Events
Bio International Conference 2016
Gene PreDiT attends Bio International Conference 2016 Gene PreDiT is attending Bio International Conference next week, from the 6th till the 9th of June 2016. This event will be held in San Francisco. Gene PreDiT will be presenting its latest results on the ongoing Clinical Trial Phase IIa for a new targeted treatment for obesity.[…]
CENTRO 2020 – International Project Approved
CENTRO-01-0247-FEDER-011112 Obesity PreDiT – A phase II, multicenter, double-blind, controlled study to evaluate the influence of the biomarker GP0044 as an indicator of body weight and fat mass loss in males after treatment with GPP846.
Bio International Conference 2015
Gene PreDiT attends Bio International Conference 2015 BIOCANT and P-BIO gathered efforts to carry out a program “BIOCANT International” to promote the internationalization of Portuguese Biotechnology sector. On the scope of this program, a Portuguese Biotechnology delegation, which includes Gene PreDiT, will be sent to Bio International. This event will be held in Philadelphia, from[…]
Biospain 2014
Gene PreDiT attends BIOSPAIN 2014 BIOCANT and P-BIO gathered efforts to carry out a program “BIOCANT International” to promote the internationalization of Portuguese Biotechnology sector. On the scope of this program, a Portuguese Biotechnology delegation,which includes Gene PreDiT, will be sent to BIOSPAIN. This event will be held in Santiago de Compostela, Spain, from 24th to[…]
